News and Trends 6 Oct 2017 British-Finnish Alliance to Bring Gene Therapy to the Masses FIT Biotech and Avacta hope to combine their technologies to produce highly specific, best-in-class gene therapy treatments. The two companies have spotted an opportunity to bring together their technologies and form a leading gene therapy system in a market that could be worth over $4.3B (€3.7B) by 2024. FIT Biotech, based in Finland, has been working on […] October 6, 2017 - 2 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 5 Oct 2017 British Biotech To Raise £12.2M to Finish Off Liquid Biopsy Technology Angle will raise £12.2M, which will allow it to acquire assets from Axela to put the finishing touches to its full liquid biopsies solution. Angle is a leader in the liquid biopsy market, the ‘holy grail’ of cancer diagnostics. The company has developed technology that recently outperformed the gold standard in the field. Angle is hoping to raise £12.2M […] October 5, 2017 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 5 Oct 2017 Dutch Clinical Trial Points to Fecal Transplant as Diabetes Treatment A small clinical trial in the Netherlands has found that a fecal transplant from a lean donor can temporarily improve diabetes symptoms in obese men. Research published in Cell Metabolism from the University of Amsterdam has found that a fecal transplant from lean men to obese men can cause a short-term improvement in insulin resistance. This […] October 5, 2017 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 4 Oct 2017 Ablynx Launches $175M IPO on Wall Street After Phase III Success Fresh from announcing positive Phase III results, Ablynx has wasted no time in filing a $175M (€148M) IPO to continue developing its nanobodies technology. On Monday, the Belgian biotech shared the news that its nanobody, caplacizumab, received encouraging results for the treatment of acquired thrombotic thrombocytopenic purpura (aTTP), a life-threatening blood disorder. This news boosted the company’s […] October 4, 2017 - 2 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 2 Oct 2017 CRISPR Gets Snubbed Again by the Nobel Prize Committee The Nobel Prize Committee has made CRISPR wait at least one more year, as it was pipped by research into the mechanisms underlying circadian rhythm. The 2017 Nobel Prize in Physiology or Medicine has been awarded to Jeffrey C. Hall, Michael Rosbash and Michael W. Young. There had been whispers that CRISPR would take home the prize, but the […] October 2, 2017 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 2 Oct 2017 Belgian Biotech Breaks New Ground in Fight Against Life-Threatening Blood Disorder Ablynx has triumphed where others have fallen by receiving positive Phase III results for the treatment of a dangerous blood disorder with caplacizumab. Ablynx develops nanobodies, molecules with the specificity of antibodies but much smaller in size. Its product, caplacizumab, has received encouraging results for the treatment of the life-threatening autoimmune blood disorder, acquired thrombotic thrombocytopenic purpura (aTTP), which […] October 2, 2017 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 2 Oct 2017 Drugs Can Now be Delivered to Cells On Demand with Light Cells can be ‘hotwired’ to take up drugs or nanoparticles by endocytosis on demand according to research carried out in the UK. Researchers at Warwick Medical School have found a way to trigger endocytosis in cells. The research, which is published in The Journal of Cell Biology, uses the cell’s own proteins to initiate the endocytosis […] October 2, 2017 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 29 Sep 2017 Austrian Scientists Turn Human Bone into Surgical Screws An alternative approach for the repair of broken bones is being developed in Austria, which would overcome major limitations of metal surgical screws. Researchers from TU Graz, Austria, are working with the start-up surgebright to develop surgical screws from donated human bone for foot and jaw surgery. Metal screws are the current standard but these have major limitations […] September 29, 2017 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 28 Sep 2017 German Pharma Enters the Clinic with Solid Tumor Treatment A Phase I study will investigate the safety and tolerability of Immatics approach to treating solid tumors. Immatics is a German biopharma based in Tuebingen, which is a leader in the field of cancer immunotherapy. It has announced today the initiation of a Phase I trial that will test the safety and tolerability of its […] September 28, 2017 - 2 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
Interview 28 Sep 2017 What are Alphabodies and How Do They Drug the Undruggable? Philip found out more about a new form of protein therapeutics being developed by Complix, which aims to drug the undruggable. Mark Vaeck, Co-Founder and CEO of Complix, has over 25 years experience in the biotech and pharma industries. His latest company Complix, a Belgian immuno-oncology biotech, is developing Alphabodies, tiny therapeutic proteins that can […] September 28, 2017 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 28 Sep 2017 Study Results Confirm that Abivax’s Treatment Towards an HIV Cure Gets Rid of Virus Abivax’s HIV cure candidate, ABX464, caused a significant drop in the viral reservoir over an extended period during a Phase IIa study. Abivax targets the immune system to cure viral diseases. The company has announced initial results from the first cohort of patients in its most recent Phase IIa trial testing its potential HIV cure, ABX464. Initial […] September 28, 2017 - 2 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
Interview 27 Sep 2017 What’s this Top Swiss VC Up To These Days? General Partner Tells All Philip caught up with Markus Hosang to find out which companies the VC is keeping an eye on after its next round of fundraising. General Partner, Markus Hosang has a strong background in pharma and VC, which serves him well when searching through the bustling biotech industry in Europe. BioMed Partners is a very active […] September 27, 2017 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email